US contract research organizations are multiplying to meet drug-makers' outsourcing needs.
US drug-makers are outsourcing more and more of their research and development, mainly to contract research organizations, according to figures released in July by the US National Science Foundation (NSF). The shift could be good news for researchers seeking positions in industry. In 1991, pharmaceutical companies spent about US$800 million on external research and development, but that skyrocketed to $13 billion in 2011, says John Jankowski, head of research and development statistics at the NSF. That growth outstrips that of any other sector. In 1991, industrial extramural research spending totalled $3.3 billion, but by 2011, spending had risen to $25.3 billion for domestic companies alone. Pharmaceutical firms' share of that total was 23% in 1991, but ballooned to 51% by 2011. Jankowski says that much of the increase comes from the outsourcing of clinical trials. The number of US contract research organizations has risen to match the demand, from around 800 in 2000 to more than 3,100 by the end of 2011, according to the Tufts Center for the Study of Drug Development in Boston, Massachusetts. - Nature 512, 106, 06 August 2014
Agency says success of new molecule for sickle cell disease shows its drug development model is working.
For the first time, a drug being developed in part by a controversial new National Institutes of Health (NIH) center aimed at speeding drug development has been picked up by a major pharmaceutical company. Baxter International has acquired the biotech company developing Aes-103, a small molecule for treating sickle cell disease. (...) - By Jocelyn Kaiser, Science, 9 July 2014
In this interview, I speak to Dr. Rob Carlson, a Principal at Biodesic, an engineering and strategic consulting firm in Seattle that provides services to governments and corporations around the globe. At the broadest level, Dr. Carlson is interested in the future role of biology as a human technology. He is the author of the book Biology is Technology: The Promise, Peril, and New Business of Engineering Life, published in 2010 by Harvard University Press; it received the PROSE award for the Best Engineering and Technology Book of 2010 and was named to the Best Books of 2010 lists by writers at both The Economist and ForeignPolicy.com. Carlson is a frequent international speaker and has served as an advisor to such diverse organisations as The Hastings Center, the PICNIC Design Festival, the UN, the OECD, the US Government, and companies ranging in size from start-ups to members of the Fortune 100. Carlson earned a doctorate in Physics from Princeton University in 1997. (...) - by Julie Gould, Nature Jobs Blog, 18 April 2014
Agency will offer I-Corps entrepreneurship boot camps.
Last fall, microbial ecologist Kei Fujimura took time away from her lab work to hunt down people with inflammatory bowel disease on Facebook. The postdoctoral researcher at the University of California, San Francisco (UCSF), was doing a bit of market research, in hopes of starting a company that would offer people with Crohn’s disease and colitis personalized microbiome sequencing data that could help them manage their conditions. She and a fellow postdoc “thought we had a pretty good shot” at commercializing the idea, she says. (...) - by Kelly Servick, Science, 24 April 2014
It's becoming essential that pharma embrace digital transformation urgently to survive, but the challenge companies face is knowing how and where to begin.
The pharmaceutical industry is currently facing a time of unprecedented change. Coming fast on the heels of the recent economic recession, the new digital economy is reshaping the way we do business. Technology now has a huge influence over business growth and capability, and the time for resisting is rapidly reaching an end. Big pharma has typically been slow to accept change, partly because of a conservative culture and partly because of fear of regulatory consequences. (...) - by Ash Rshi, March 13, 2014
Julien Hering, PhD's insight:
Digital transformation for big pharma at all levels : marketing, medical affairs... but also in R&D, virtual teams, and e-health!
Eli Lilly and Co on Thursday said its experimental drug to treat major depression failed to meet it primary goal in three late-stage trials and the drugmaker will not seek approval of the medicine for that condition.
The drug edivoxetine, a member of a family of medicines called norepinephrine reuptake inhibitors, was tested in combination with a member of a widely used class of depression treatments called selective serotonin reuptake inhibitors (SSRIs) in each of the three trials.
But after eight weeks of treatment, the combination of drugs that included edivoxetine did not prove superior to the SSRIs alone, thereby failing the main goal of the study. - PharmaGossip, December 5, 2013
Un rythme d’innovation accéléré, de nouveaux business models... L’industrie pharmaceutique n’est pas, comme les autres secteurs, épargné par la nécessité de s’adapter au renouveau technologique. (...) - par Quentin Capelle, L'Atelier Disruptive Innovation,14 octobre 2013
A list of 25 biotech companies, ranked by their market capitalization for the latest quarter that they furnished figures on their numbers of outstanding shares.
Last year, GEN published a list of the top 25 biotech companies. So, who would make the list this year? Find out by checking out this updated list of 25 biotech companies ranked by their market capitalization for the latest quarter that they furnished figures on their numbers of outstanding shares.
Overall, the past year has been mostly very good to biotechs where market cap is concerned, the result of a stock market surge that has not only lifted prices well into double-digits for most of the companies on the list, but also finally jumpstarted the market for initial public offerings after several years of spinning its wheels. (...) Genetic Engineering & Biotechnology ews, July 22, 2013
En croissance grâce à ses exportations, l’industrie du médicament voit son marché français chuter. Et se dit victime des plans d’économies pour la sécurité sociale et de multiples taxes. Alors même qu’un député veut lui en imposer une nouvelle, pour la recherche dans le cancer des enfants… (...) - L'Usine Nouvelle, 14/06/2013
A court has ordered the European Medicines Agency (EMA) to keep data from two drug companies confidential, running counter to EMA's recent push to share clinical and nonclinical information as widely as possible. The temporary injunction from the General Court of the European Union backs two drug firms on the U.S. side of the pond: AbbVie, headquartered in North Chicago, Illinois, and InterMune in Brisbane, California. (...) - ScienceInsider, by Jennifer Couzin-Frankel on 30 April 2013
Le Tour de France de LaBiotech à vélo vise à réaliser un panorama filmé des entreprises de biotechnologies pour le partager au monde entier.
Nous sommes les co-fondateurs du site LaBiotech.fr qui centralise l’actualité des Biotechnologies tout en créant du contenu exclusif pour vous informer du secteur rapidement, simplement et gratuitement. Lancé en décembre 2012, il rassemble désormais plus de 300 abonnés et 2000 visiteurs uniques.
Avec deux vélos, nos jambes et du soutien, nous souhaitons parcourir la France pour interviewer les différentes entreprises des Biotechnologies. Le trajet et les interviews, tous les deux filmés, seront rassemblés dans un documentaire sous-titré en anglais, allemand et espagnol. Le but étant d'établir un panorama du secteur des biotechnologies françaises et de le partager gratuitement avec le monde entier.
Le Tour débutera par un prologue en Ile de France du 1er au 12 juillet et partira de Paris le dimanche 14 juillet jusqu'au vendredi 2 aout. Les grandes destinations seront Strasbourg, puis Lyon, Marseille, Bordeaux et Nantes. Pour réaliser ce tour, nous avons besoin d'un budget de 4000€ composé de matériel photo/vidéo, de matériel vélo et des frais de déplacement. Nous avons besoin de vous pour nous aider et permettre de réaliser cette expérience qui sera positive pour le secteur des biotechnologies françaises ainsi que pour la France.
Ce projet vous plait ? Alors suivez-nous, partagez-nous et soutenez-nous !
Baisses de prix, impact des génériques : le marché du médicament devrait continuer de décliner cette année en France, selon une étude d’IMS Health. Une embellie serait possible en 2014, en fonction des décisions politiques.
Alors que les plans sociaux se poursuivent dans l’industrie pharmaceutique, les perspectives sur le marché français sont toujours sombres. Après avoir connu la première récession de son histoire en 2012, avec une chute de 2,3% en valeur, le marché des médicaments en ville devrait s’effondrer de 3,4% cette année, selon l’étude présentée ce mardi par le cabinet de conseil pour les acteurs de la santé IMS Health. (...) L'Usine Nouvelle, par Gaëlle Fleitour, 19 mars 2013
AstraZeneca a lancé Bipolife® : le premier outil interactif à visée psychoéducative spécifiquement dédié aux troubles bipolaires. Développé en collaboration avec l’entreprise Ubisoft et sous la supervision d’un comité scientifique, Bipolife® a pour objectif d’aider les personnes souffrant de troubles bipolaires à mieux comprendre leur maladie et à identifier les comportements quotidiens qui influent sur son évolution. (...) - MyPharma, 01/04/2013
Firms fight for the right to patent natural products and processes.
Guidelines that forbid patents on a wide array of natural products, phenomena and principles have many in the biotechnology and pharmaceutical industries worried about the future of their business. (...) - by Erika Check-Hayden, Nature, 08 July 2014
In this month’s Windback Wednesday series, we’re all about entrepreneurship: what it takes to be one, how to become one and more. But if you’re based in London, it’s not so easy. Although it’s got the brains and research centres to make it a hub, setting up shop in London is the tricky part. In this podcast, I speak to Kit Malthouse, the Deputy Mayor of London for Business and Enterprise, and find out how London is preparing to become the next biotech hub. (...) by Julie Gould, Nature, 23 April 2014
Y Combinator has high hopes for low-cost biotech innovation.
Y Combinator, a company that backs technology start-ups, is famous for its early support of successful online services such as Airbnb and Dropbox. It historically has invested a few thousand dollars into web-based businesses that require only small grants to get up and running at their earliest stages. But the programme is now expanding its reach to back biotechnology start-ups, says company president Sam Altman. (...) - by Richard Van Noorden, Nature, 23 April 2014
Ses médicaments les plus profitables déjà ou sur le point de tomber dans le domaine public, le groupe français mise principalement sur 7 nouvelles plateformes de croissance et notamment sur les vaccins, la santé animale et les partenariats de recherche. (...) - par Maxime Michallet, Santé Publique & Santé Privée, 22 mars 2014
Le britannique cesse de rémunérer les médecins pour la promotion de ses produits. L'industrie pharmaceutique serait-elle prête à faire sa révolution culturelle ? En réformant ses pratiques commerciales, le britannique GSK donne en tout cas un signal dans ce sens. (...) - par Catherine Ducruet, Les Echos, 18/12/2013
After years in the doldrums, research into neurological disorders is about to undergo a major change of direction.
In a sign that psychiatric-disease research is entering a new era, the pharmaceutical giant Novartis has hired an expert in neural circuitry, rather than pharmacology, to head its relaunched neuroscience division. (...) - by Alison Abbot, Nature, 08 October 2013
We conducted randomized clinical trials to examine the impact of direct-to-consumer advertisements on the efficacy of a branded drug. We compared the objectively measured, physiological effect of Claritin (Merck & Co.), a leading antihistamine medication, across subjects randomized to watch a movie spliced with advertisements for Claritin or advertisements for Zyrtec (McNeil), a competitor antihistamine. Among subjects who test negative for common allergies, exposure to Claritin advertisements rather than Zyrtec advertisements increases the efficacy of Claritin. We conclude that branded drugs can interact with exposure to television advertisements. (...) - by Kamenica Eet al., PNAS August 6, 2013 vol. 110 no. 32 12931-12935
Neurotrophins and their receptors modulate multiple signalling pathways to regulate neuronal survival and to maintain axonal and dendritic networks and synaptic plasticity. Neurotrophins have potential for the treatment of neurological diseases. However, their therapeutic application has been limited owing to their poor plasma stability, restricted nervous system penetration and, importantly, the pleiotropic actions that derive from their concomitant binding to multiple receptors. One strategy to overcome these limitations is to target individual neurotrophin receptors — such as tropomyosin receptor kinase A (TRKA), TRKB, TRKC, the p75 neurotrophin receptor or sortilin — with small-molecule ligands. Such small molecules might also modulate various aspects of these signalling pathways in ways that are distinct from the programmes triggered by native neurotrophins. By departing from conventional neurotrophin signalling, these ligands might provide novel therapeutic options for a broad range of neurological indications. (...) - by Frank M. Longo& Stephen M. Massa, Nature Reviews Drug Discovery12,507–525(2013)
So, do drug companies really spend more money on marketing than on R&D? In the Pipeline takes a look at that contention, and the cold hard facts are these: Probably not. But it's hard to tell for sure.
Derek Lowe's blog dug up the numbers and calculated spending as a percentage of revenue. In the case of R&D, that's pretty easy to determine; companies break that number out as its own line item. As for marketing, sales expenses are lumped into a category dubbed SG&A, or sales, general and administrative expenses. And as Lowe notes, that category includes lots more than sales spending. Executive salaries, for instance. (...) - by Tracy Staton, FiercePharma, May 21, 2013
Target-identification and mechanism-of-action studies have important roles in small-molecule probe and drug discovery. Biological and technological advances have resulted in the increasing use of cell-based assays to discover new biologically active small molecules. Such studies allow small-molecule action to be tested in a more disease-relevant setting at the outset, but they require follow-up studies to determine the precise protein target or targets responsible for the observed phenotype. Target identification can be approached by direct biochemical methods, genetic interactions or computational inference. In many cases, however, combinations of approaches may be required to fully characterize on-target and off-target effects and to understand mechanisms of small-molecule action. (...) - by Schenone Met al., Nature Chemical Biology9,232–240(2013)
Which company takes the title? It may come as no surprise that pharma giant Pfizer claims the lead spot, however the sequence that follows shows interesting trends. In this article I’ll share bioscience companies with ideal digital presence and touch on available apps to score yours. The performance indictor was the Bio Web Score Absolute, a free tool measuring the digital presence of life science businesses. (...) - Biowebspin Public Place, by Sara Ahmadi, 26/04/2013